MDxHealth (MDXH) Cash & Equivalents (2020 - 2026)

MDxHealth (MDXH) has 7 years of Cash & Equivalents data on file, last reported at $43.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 34.29% year-over-year to $43.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.2 million (down 34.29% YoY) and the FY2025 annual result came in at $46.8 million, up 109.11% from the prior year.
• Cash & Equivalents advanced to $43.2 million in Q1 2026 per MDXH's latest filing, from $29.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $65.7 million in Q1 2025, with the low at $33081.0 in Q2 2025.
• Average Cash & Equivalents over 5 years is $33.0 million, with a median of $32.4 million recorded in 2023.
• The widest YoY moves for Cash & Equivalents: up 353.1% in 2025, down 99.85% in 2025.
• MDxHealth's Cash & Equivalents stood at $15.5 million in 2022, then jumped by 44.36% to $22.4 million in 2023, then jumped by 109.11% to $46.8 million in 2024, then slumped by 37.96% to $29.0 million in 2025, then soared by 48.64% to $43.2 million in 2026.
• Business Quant data shows MDXH's Cash & Equivalents at $43.2 million in Q1 2026, $29.0 million in Q4 2025, and $32.0 million in Q3 2025.